Fischer, K.; Przepiera-Będzak, H.; Brzosko, I.; Sawicki, M.; Walecka, A.; Brzosko, M.
Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies—Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus. Biomolecules 2022, 12, 1328.
https://doi.org/10.3390/biom12101328
AMA Style
Fischer K, Przepiera-Będzak H, Brzosko I, Sawicki M, Walecka A, Brzosko M.
Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies—Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus. Biomolecules. 2022; 12(10):1328.
https://doi.org/10.3390/biom12101328
Chicago/Turabian Style
Fischer, Katarzyna, Hanna Przepiera-Będzak, Iwona Brzosko, Marcin Sawicki, Anna Walecka, and Marek Brzosko.
2022. "Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies—Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus" Biomolecules 12, no. 10: 1328.
https://doi.org/10.3390/biom12101328
APA Style
Fischer, K., Przepiera-Będzak, H., Brzosko, I., Sawicki, M., Walecka, A., & Brzosko, M.
(2022). Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies—Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus. Biomolecules, 12(10), 1328.
https://doi.org/10.3390/biom12101328
